BD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance

- Announces full fiscal year adjusted revenues of $10.302 billion, an increase of 22.0 percent, or 29.5 percent on a currency-neutral basis. On a comparable, currency-neutral basis, adjusted revenues grew 5.3 percent for the full year. As reported, full-year revenues increased 21.7 percent to $10.282 billion.

- For the full fiscal year, adjusted diluted earnings per share of $7.16 increased 10.2 percent, or 21.2 percent on a currency-neutral basis. As reported, full-year diluted earnings per share were $3.35.

- Expects full-year fiscal 2016 adjusted diluted earnings per share to be between $8.37 and $8.44 including the estimated unfavorable impact from foreign currency. This represents growth of approximately 17.0 to 18.0 percent. On a currency-neutral basis, full-year fiscal 2016 adjusted diluted earnings per share are expected to be between $8.73 and $8.80, which represents growth of 22.0 to 23.0 percent. These fiscal 2016 earnings per share expectations include approximately 22.0 percentage points of accretion from the CareFusion acquisition. As reported, the Company expects full fiscal year diluted earnings per share to be between $6.57 and $6.64.

Nov 04, 2015, 06:00 ET from BD (Becton, Dickinson and Company)

FRANKLIN LAKES, N.J., Nov. 4, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly adjusted revenues of $3.067 billion for the fourth fiscal quarter ended September 30, 2015, an increase of 39.3 percent over the prior-year period as reported, or 49.1 percent on a currency-neutral basis.  On a comparable, currency-neutral basis, fourth quarter adjusted revenues grew 5.1 percent.  As reported, fourth quarter revenues were $3.059 billion.  For the full fiscal year ended September 30, 2015, BD reported adjusted revenues of $10.302 billion, an increase of 22.0 percent over the prior-year period as reported, or 29.5 percent on a currency-neutral basis.  On a comparable, currency-neutral basis, full fiscal year adjusted revenues grew 5.3 percent.  As reported, full fiscal year revenues were $10.282 billion.

"Fiscal 2015 was a significant year for BD with the successful completion of the largest acquisition in the Company's history," said Vincent A. Forlenza, Chairman, CEO and President. "We are very proud of our strong fourth quarter and fiscal year 2015 results, which exceeded our expectations.  We enter fiscal 2016 with continued confidence in our ability to execute our strategy, deliver against our financial commitments, and return value to our shareholders."

All "comparable" basis revenue growth rates presented throughout this release include the results of CareFusion in the current and prior-year periods.  For reconciliations of these revenue amounts and growth rates to the most directly comparable GAAP measures, please refer to the tables at the end of this release.

Fourth Quarter and Full Year Fiscal 2015 Operating Results
Adjusted diluted earnings per share were $1.94, compared with $1.74 in the prior-year period. This represents an increase of 11.5 percent, or 21.8 percent on a currency-neutral basis. On a reported basis, diluted earnings per share for the fourth quarter were $0.84 compared with $1.53 in the prior-year period.

For the full fiscal year ended September 30, 2015, adjusted diluted earnings per share were $7.16, compared with $6.50 in the prior-year period. This represents an increase of 10.2 percent, or 21.2 percent on a currency-neutral basis. On a reported basis, diluted earnings per share were $3.35, compared with $5.99 in the prior-year period.

Current and prior-year adjusted results exclude the impact of the non-cash amortization of intangible assets and other certain specified items. These specified items are detailed in the accompanying reconciliation of reported diluted earnings per share to adjusted diluted earnings per share.

Segment Results
In the BD Medical segment, worldwide adjusted revenues for the quarter were $2.091 billion, an increase of 75.3 percent over the prior-year period as reported, or 86.6 percent on a currency-neutral basis.  On a comparable, currency-neutral basis, adjusted Medical revenues grew 5.2 percent, which reflects strong sales across the Medication Management Solutions, Medication and Procedural Solutions, Pharmaceutical Systems, and Diabetes Care units, partially offset by a decline in the Respiratory Solutions unit.   On a reported basis, Medical revenues were $2.083 billion.

For the twelve-month period ended September 30, 2015, BD Medical adjusted revenues of $6.480 billion increased 41.7 percent over the prior-year period as reported, or 50.2 percent on a currency-neutral basis.  On a comparable, currency-neutral basis, adjusted revenues grew 5.5 percent.  On a reported basis, revenues were $6.460 billion.

In the BD Life Sciences segment, worldwide revenues for the quarter were $976 million, a decrease of 3.3 percent from the prior-year period, or an increase of 4.8 percent on a currency-neutral basis. The segment's results reflect solid growth in the Preanalytical Systems and Diagnostic Systems units, and moderate growth in the Biosciences unit.

For the twelve-month period ended September 30, 2015, BD Life Sciences revenues of $3.822 billion decreased 1.3 percent from the prior-year period, and increased 5.0 percent on a currency-neutral basis.

Geographic Results
Fourth quarter adjusted revenues in the U.S. of $1.640 billion represent an increase of 88.3 percent over the prior-year period as reported. On a comparable basis, adjusted U.S. revenues increased 4.6 percent. Within the BD Medical segment, growth was driven by strong sales in the Medication Management Solutions and Medication and Procedural Solutions units, partially offset by a decline in the Respiratory Systems unit.  Growth in the BD Life Sciences segment was driven by strong performance in the Biosciences unit.  On a reported basis, U.S. revenues were $1.632 billion.

Revenues outside of the U.S. were $1.427 billion, representing an increase of 7.2 percent over the prior-year period, or an increase of 23.4 percent on a currency-neutral basis. On a comparable, currency-neutral basis, international revenues grew 5.5 percent which reflects continued strength in Western Europe.

For the twelve-month period ended September 30, 2015, adjusted revenues in the U.S. were $5.090 billion, an increase of 49.0 percent over the prior-year period as reported.  On a comparable basis, U.S. revenues grew 4.1 percent. On a reported basis, U.S. revenues were $5.069 billion.  Revenues outside of the U.S. were $5.213 billion, an increase of 3.6 percent over the prior-year period as reported, or an increase of 16.2 percent on a currency-neutral basis. On a comparable, currency-neutral basis, revenues outside the U.S. grew 6.6 percent.  

Fiscal 2016 Outlook for Full Year
The Company estimates that currency-neutral adjusted revenues for the full fiscal year 2016, including the accretion from the acquisition of CareFusion, will increase 24.5 to 25.0 percent. Including the impact of foreign currency, adjusted revenues are expected to increase 23.0 to 23.5 percent.  On a comparable, currency-neutral basis, the Company estimates organic adjusted revenues will increase 4.5 to 5.0 percent. As reported, the Company expects full fiscal year revenues to increase 23.0 to 23.5 percent.

The Company expects adjusted diluted earnings per share to be between $8.37 and $8.44 for the full fiscal year 2016 including the estimated unfavorable impact from foreign currency. This represents growth of approximately 17.0 to 18.0 percent.  On a currency-neutral basis, full-year fiscal 2016 adjusted diluted earnings per share are expected to be between $8.73 and $8.80, which represents growth of 22.0 to 23.0 percent over 2015 adjusted diluted earnings per share of $7.16.  Adjusted diluted earnings per share exclude, among other specified items, the non-cash amortization of intangible assets, and include approximately 22.0 percentage points of accretion from the CareFusion acquisition.  As reported, the Company expects full fiscal year diluted earnings per share to be between $6.57 and $6.64.

Conference Call Information
A conference call regarding BD's fourth quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Wednesday, November 4, 2015.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Wednesday, November 11, 2015, confirmation number 51724857.

Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers.  Percentages and earnings per share amounts presented are calculated from the underlying amounts.

About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.

***

This press release, including the section entitled "Fiscal 2016 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially.  These factors include, but are not limited to: risks relating to the integration of CareFusion's operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; potential cuts in governmental healthcare spending, which could result in reduced demand for our product or downward pricing pressure; measures to contain healthcare costs; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors including technological advances and new products introduced by competitors; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; increases in energy costs and their effect on, among other things, the cost of producing BD's products; efficacy or safety concerns relating to product recalls; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws and regulations impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

 

 

BECTON DICKINSON AND COMPANY












CONSOLIDATED INCOME STATEMENTS












(Unaudited; Amounts in millions, except share and per share data)


























Three Months Ended September 30,




2015



2014



% Change















REVENUES


$

3,059


$

2,202



38.9














Cost of products sold



1,630



1,099



48.2



Selling and administrative expense



756



561



34.8



Research and development expense



196



140



39.6



Acquisition-related costs



182



-



        NM 



TOTAL OPERATING COSTS












     AND EXPENSES



2,764



1,801



53.5















OPERATING INCOME



296



401



(26.3)















Interest expense



(99)



(36)



        NM 



Interest income



(5)



10



        NM 



Other (expense) income, net



(2)



1



        NM 















INCOME BEFORE INCOME TAXES



190



376



(49.6)















Income tax provision



9



76



(88.4)















NET INCOME


$

181


$

301



(39.9)















EARNINGS PER SHARE
























Basic Earnings per Share


$

0.86


$

1.56



(44.9)



Diluted Earnings per Share


$

0.84


$

1.53



(45.1)















AVERAGE SHARES OUTSTANDING (in thousands)
























     Basic



210,985



192,332






     Diluted



215,719



196,460


















NM - Not Meaningful












 

 

BECTON DICKINSON AND COMPANY












CONSOLIDATED INCOME STATEMENTS












(Unaudited; Amounts in millions, except share and per share data)


























Twelve Months Ended September 30,




2015



2014



% Change















REVENUES


$

10,282


$

8,446



21.7













Cost of products sold



5,587



4,145



34.8



Selling and administrative expense



2,563



2,145



19.5



Research and development expense



632



550



14.8



Acquisition-related costs



426



-



        NM 



TOTAL OPERATING COSTS












     AND EXPENSES



9,207



6,840



34.6















OPERATING INCOME



1,074



1,606



(33.1)















Interest expense



(371)



(135)



        NM 



Interest income



15



46



(67.0)



Other income, net 



21



5



        NM 















INCOME BEFORE INCOME TAXES



739



1,522



(51.4)















Income tax provision



44



337



(87.0)















NET INCOME


$

695


$

1,185



(41.3)















EARNINGS PER SHARE
























Basic Earnings per Share


$

3.43


$

6.13



(44.0)



Diluted Earnings per Share


$

3.35


$

5.99



(44.1)















AVERAGE SHARES OUTSTANDING (in thousands)
























     Basic



202,537



193,299






     Diluted



207,509



197,709






























NM - Not Meaningful












 

 

 

BECTON DICKINSON AND COMPANY

























SUPPLEMENTAL REVENUE INFORMATION

























REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES




















Three Months Ended September 30,

























(Unaudited; Amounts in millions)

































































A


B


C



D=(A-B)/B


E=(C-B)/B













As Reported


Adjusted



 % Change 












2015


2014


2015



 Reported 



Adjusted










BD MEDICAL

























   Medication and Procedural Solutions


$

481


$

257


$

481



87.0



87.0










   Medication Management Solutions



390



-



390



        NM 



        NM 










   Diabetes Care



130



123



130



5.7



5.7










   Pharmaceutical Systems



78



76



78



2.5



2.5










   Respiratory Solutions



133



-



133



        NM 



        NM 










   Deferred Revenue Adjustment *



(8)



-



-



        NM 



-










TOTAL


$

1,203


$

456


$

1,211



164.1



165.8



































BD LIFE SCIENCES

























   Preanalytical Systems


$

173


$

171


$

173



1.5



1.5










   Diagnostic Systems



146



148



146



(1.8)



(1.8)










   Biosciences



110



96



110



14.5



14.5










TOTAL


$

429


$

415


$

429



3.3



3.3




























































TOTAL UNITED STATES


$

1,632


$

871


$

1,640



87.4



88.3














































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.


























NM - Not Meaningful

























 

 

BECTON DICKINSON AND COMPANY

















SUPPLEMENTAL REVENUE INFORMATION













REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL









Three Months Ended September 30, (continued)















(Unaudited; Amounts in millions)

























A


B


C



D=(A-B)/B


E=(A-B-C)/B









As Reported


FX



 % Change 









2015


2014


Impact



 Reported 



 FXN 







BD MEDICAL






















   Medication and Procedural Solutions


$

356


$

331


$

(52)



7.6



23.3







   Medication Management Solutions



89



-



(14)



        NM 



        NM 







   Diabetes Care



127



141



(23)



(10.2)



6.0







   Pharmaceutical Systems



254



265



(39)



(4.0)



10.8







   Respiratory Solutions



54



-



(6)



        NM 



        NM 







TOTAL


$

880


$

737


$

(134)



19.4



37.6





























BD LIFE SCIENCES






















   Preanalytical Systems


$

175


$

187


$

(30)



(6.4)



9.8







   Diagnostic Systems



196



202



(29)



(2.9)



11.5







   Biosciences



176



205



(22)



(14.3)



(3.5)







TOTAL


$

547


$

594


$

(81)



(7.9)



5.8



















































TOTAL INTERNATIONAL


$

1,427


$

1,331


$

(216)



7.2



23.4









































































NM - Not Meaningful


















 

BECTON DICKINSON AND COMPANY





















SUPPLEMENTAL REVENUE INFORMATION


















REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL
















Three Months Ended September 30, (continued)

















(Unaudited; Amounts in millions)


































A


B


C


D



E=(A-B)/B



F=(A-B-D)/B



G=(C-B)/B



H=(C-B-D)/B
















 % Change 



As Reported


Adjusted


FX












Adjusted



2015


2014


2015


Impact



 Reported 



 FXN 



 Adjusted 



 FXN 

BD MEDICAL

























   Medication and Procedural Solutions


$

836


$

588


$

836


$

(52)



42.3



51.2



42.3



51.2

   Medication Management Solutions



479



-



479



(14)



        NM 



        NM 



        NM 



        NM 

   Diabetes Care



257



264



257



(23)



(2.8)



5.8



(2.8)



5.8

   Pharmaceutical Systems



332



341



332



(39)



(2.6)



9.0



(2.6)



9.0

   Respiratory Solutions



187



-



187



(6)



        NM 



        NM 



        NM 



        NM 

   Deferred Revenue Adjustment *



(8)



-



-



-



        NM 



        NM 



-



-

TOTAL


$

2,083


$

1,193


$

2,091


$

(134)



74.7



85.9



75.3



86.6

























BD LIFE SCIENCES

























   Preanalytical Systems


$

349


$

358


$

349


$

(30)



(2.6)



5.8



(2.6)



5.8

   Diagnostic Systems



342



350



342



(29)



(2.4)



5.9



(2.4)



5.9

   Biosciences



286



301



286



(22)



(5.1)



2.2



(5.1)



2.2

TOTAL


$

976


$

1,009


$

976


$

(81)



(3.3)



4.8



(3.3)



4.8


















































TOTAL REVENUES


$

3,059


$

2,202


$

3,067


$

(216)



38.9



48.7



39.3



49.1




































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.


























NM - Not Meaningful























 

 

BECTON DICKINSON AND COMPANY





















SUPPLEMENTAL REVENUE INFORMATION


















REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES










Twelve Months Ended September 30,




















(Unaudited; Amounts in millions)





























































A


B


C



D=(A-B)/B



E=(C-B)/B













As Reported


Adjusted



 % Change 












2015


2014


2015



 Reported 



Adjusted










BD MEDICAL

























   Medication and Procedural Solutions


$

1,483


$

1,016


$

1,483



46.0



46.0










   Medication Management Solutions



832



-



832



        NM 



        NM 










   Diabetes Care



491



481



491



2.2



2.2










   Pharmaceutical Systems



304



303



304



0.3



0.3










   Respiratory Solutions



297



-



297



        NM 



        NM 










   Deferred Revenue Adjustment *



(20)



-



-



        NM 



-










TOTAL


$

3,386


$

1,799


$

3,407



88.2



89.4



































BD LIFE SCIENCES

























   Preanalytical Systems


$

689


$

678


$

689



1.7



1.7










   Diagnostic Systems



592



573



592



3.1



3.1










   Biosciences



402



366



402



9.7



9.7










TOTAL


$

1,683


$

1,617


$

1,683



4.0



4.0




























































TOTAL UNITED STATES


$

5,069


$

3,417


$

5,090



48.4



49.0














































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.


























NM - Not Meaningful






















 

 

BECTON DICKINSON AND COMPANY





















SUPPLEMENTAL REVENUE INFORMATION

















REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL













Twelve Months Ended September 30, (continued)

















(Unaudited; Amounts in millions)




























A


B


C



D=(A-B)/B


E=(A-B-C)/B












As Reported


FX



 % Change 












2015


2014


Impact



 Reported 



 FXN 










BD MEDICAL

























   Medication and Procedural Solutions


$

1,367


$

1,292


$

(147)



5.8



17.2










   Medication Management Solutions



201



-



(34)



        NM 



        NM 










   Diabetes Care



521



557



(69)



(6.5)



6.0










   Pharmaceutical Systems



863



926



(124)



(6.8)



6.7










   Respiratory Solutions



122



-



(14)



        NM 



        NM 










TOTAL


$

3,074


$

2,774


$

(389)



10.8



24.8



































BD LIFE SCIENCES

























   Preanalytical Systems


$

701


$

734


$

(90)



(4.5)



7.8










   Diagnostic Systems



708



728



(84)



(2.8)



8.7










   Biosciences



730



793



(69)



(7.9)



0.8










TOTAL


$

2,139


$

2,255


$

(244)



(5.1)



5.7




























































TOTAL INTERNATIONAL


$

5,213


$

5,029


$

(633)



3.6



16.2





















































































NM - Not Meaningful






















 

 

BECTON DICKINSON AND COMPANY

























SUPPLEMENTAL REVENUE INFORMATION






















REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL



















Twelve Months Ended September 30, (continued)



















(Unaudited; Amounts in millions)





































A


B


C


D



E=(A-B)/B



F=(A-B-D)/B



G=(C-B)/B



H=(C-B-D)/B
















 % Change 



As Reported


Adjusted


FX












Adjusted



2015


2014


2015


Impact



 Reported 



 FXN 



 Adjusted 



 FXN 

BD MEDICAL

























   Medication and Procedural Solutions


$

2,850


$

2,307


$

2,850


$

(147)



23.5



29.9



23.5



29.9

   Medication Management Solutions



1,033



-



1,033



(34)



        NM 



        NM 



        NM 



        NM 

   Diabetes Care



1,012



1,037



1,012



(69)



(2.4)



4.3



(2.4)



4.3

   Pharmaceutical Systems



1,167



1,229



1,167



(124)



(5.0)



5.1



(5.0)



5.1

   Respiratory Solutions



419



-



419



(14)



        NM 



        NM 



        NM 



        NM 

   Deferred Revenue Adjustment *



(20)



-



-



-



        NM 



        NM 



-



-

TOTAL


$

6,460


$

4,573


$

6,480


$

(389)



41.3



49.8



41.7



50.2

























BD LIFE SCIENCES

























   Preanalytical Systems


$

1,391


$

1,412


$

1,391


$

(90)



(1.5)



4.9



(1.5)



4.9

   Diagnostic Systems



1,299



1,301



1,299



(84)



(0.2)



6.3



(0.2)



6.3

   Biosciences



1,132



1,159



1,132



(69)



(2.4)



3.6



(2.4)



3.6

TOTAL


$

3,822


$

3,872


$

3,822


$

(244)



(1.3)



5.0



(1.3)



5.0


















































TOTAL REVENUES


$

10,282


$

8,446


$

10,302


$

(633)



21.7



29.2



22.0



29.5




































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.


























NM - Not Meaningful

























 

 

 

BECTON DICKINSON AND COMPANY




























SUPPLEMENTAL INFORMATION




























RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED REVENUE CHANGE - UNITED STATES


















Three Months Ended September 30,




























(Unaudited; Amounts in millions)


























































A


B


C=A+B



D



E



F=D+E



G=(C-F)/F












Deferred 






BD


CFN


Comparable



Comparable









Reported


Revenue


Adjusted



Reported


Reported


Historical



Adjusted









2015


Adjustment


2015



2014


2014


2014



% Change







BD MEDICAL 




























   Medication and Procedural Solutions


$

481


$

-


$

481


$

257


$

199


$

456



5.4







   Medication Management Solutions



390



-



390



-



346



346



12.7







   Diabetes Care



130



-



130



123



-



123



5.7







   Pharmaceutical Systems



78



-



78



76



-



76



2.5







   Respiratory Solutions



133



-



133



-



152



152



(12.5)







   Deferred Revenue Adjustment *



(8)



8



-



-



-



-



-







TOTAL


$

1,203


$

8


$

1,211


$

456


$

697


$

1,152



5.1


































BD LIFE SCIENCES




























   Preanalytical Systems


$

173


$

-


$

173


$

171


$

-


$

171



1.5







   Diagnostic Systems



146



-



146



148



-



148



(1.8)







   Biosciences



110



-



110



96



-



96



14.5







TOTAL


$

429


$

-


$

429


$

415


$

-


$

415



3.3






























































TOTAL UNITED STATES


$

1,632


$

8


$

1,640


$

871


$

697


$

1,567



4.6






















































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

 

BECTON DICKINSON AND COMPANY



















SUPPLEMENTAL INFORMATION



















RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE FXN REVENUE CHANGE - INTERNATIONAL










Three Months Ended September 30, (continued)



















(Unaudited; Amounts in millions)


































A


B


C



D=B+C


E



F=(A-D-E)/D






BD


CFN



Comparable


Comparable



Comparable



Reported


Reported


Reported



Historical


FX



FXN



2015


2014


2014



2014


Impact



% Change

BD MEDICAL 



















   Medication and Procedural Solutions


$

356


$

331


$

60


$

391


$

(52)



4.5

   Medication Management Solutions



89



-



97



97



(14)



5.5

   Diabetes Care



127



141



-



141



(23)



6.0

   Pharmaceutical Systems



254



265



-



265



(39)



10.8

   Respiratory Solutions



54



-



69



69



(6)



(12.2)

TOTAL


$

880


$

737


$

226


$

963


$

(134)



5.4




















BD LIFE SCIENCES



















   Preanalytical Systems


$

175


$

187


$

-


$

187


$

(30)



9.8

   Diagnostic Systems



196



202



-



202



(29)



11.5

   Biosciences



176



205



-



205



(22)



(3.5)

TOTAL


$

547


$

594


$

-


$

594


$

(81)



5.8







































TOTAL INTERNATIONAL


$

1,427


$

1,331


$

226


$

1,557


$

(216)



5.5



















 

 

BECTON DICKINSON AND COMPANY




























SUPPLEMENTAL INFORMATION




























RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED FXN REVENUE CHANGE - TOTAL



















Three Months Ended September 30, (continued)




























(Unaudited; Amounts in millions)


























































A


B


C=A+B


D


E



F=D+E


G



H=(C-F-G)/F



























Comparable









Deferred 





BD


CFN



Comparable


Comparable



Adjusted





Reported


Revenue


Adjusted


Reported


Reported



Historical


FX



FXN





2015


Adjustment


2015


2014


2014



2014


Impact



% Change



BD MEDICAL 




























   Medication and Procedural Solutions


$

836


$

-


$

836


$

588


$

258


$

846


$

(52)



5.0




   Medication Management Solutions



479



-



479



-



443



443



(14)



11.1




   Diabetes Care



257



-



257



264



-



264



(23)



5.8




   Pharmaceutical Systems



332



-



332



341



-



341



(39)



9.0




   Respiratory Solutions



187



-



187



-



220



220



(6)



(12.4)




   Deferred Revenue Adjustment *



(8)



8



-



-



-



-



-



-




TOTAL


$

2,083


$

8


$

2,091


$

1,193


$

922


$

2,115


$

(134)



5.2































BD LIFE SCIENCES




























   Preanalytical Systems


$

349


$

-


$

349


$

358


$

-


$

358


$

(30)



5.8




   Diagnostic Systems



342



-



342



350



-



350



(29)



5.9




   Biosciences



286



-



286



301



-



301



(22)



2.2




TOTAL


$

976


$

-


$

976


$

1,009


$

-


$

1,009


$

(81)



4.8



























































TOTAL REVENUES


$

3,059


$

8


$

3,067


$

2,202


$

922


$

3,124


$

(216)



5.1



















































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

 

 

BECTON DICKINSON AND COMPANY




























SUPPLEMENTAL INFORMATION




























RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED REVENUE CHANGE - UNITED STATES


















Twelve Months Ended September 30,




























(Unaudited; Amounts in millions)


























































A


B


C=A+B


D


E=C+D



F


G


H=F+G



I=(E-H)/H















Comparable


















Deferred 





CFN


Historical


BD


CFN


Comparable



Comparable



Reported


Revenue


Adjusted


Reported


Adjusted


Reported


Reported


Historical



Adjusted



2015


Adjustment


2015


1st Half 2015 **


2015


2014


2014


2014



% Change

BD MEDICAL 




























   Medication and Procedural Solutions


$

1,483


$

-


$

1,483


$

427


$

1,910


$

1,016


$

800


$

1,816



5.2

   Medication Management Solutions



832



-



832



843



1,675



-



1,607



1,607



4.2

   Diabetes Care



491



-



491



-



491



481



-



481



2.2

   Pharmaceutical Systems



304



-



304



-



304



303



-



303



0.3

   Respiratory Solutions



297



-



297



333



630



-



604



604



4.3

   Deferred Revenue Adjustment *



(20)



20



-



-



-



-



-



-



-

TOTAL


$

3,386


$

20


$

3,407


$

1,603


$

5,010


$

1,799


$

3,011


$

4,810



4.2




























BD LIFE SCIENCES




























   Preanalytical Systems


$

689


$

-


$

689


$

-


$

689


$

678


$

-


$

678



1.7

   Diagnostic Systems



592



-



592



-



592



573



-



573



3.1

   Biosciences



402



-



402



-



402



366



-



366



9.7

TOTAL


$

1,683


$

-


$

1,683


$

-


$

1,683


$

1,617


$

-


$

1,617



4.0
























































TOTAL UNITED STATES


$

5,069


$

20


$

5,090


$

1,603


$

6,693


$

3,417


$

3,011


$

6,427



4.1
















































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.





























** For the quarters ended December 31, 2014 and March 31, 2015























 

 

BECTON DICKINSON AND COMPANY

























SUPPLEMENTAL INFORMATION

























RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE FXN REVENUE CHANGE - INTERNATIONAL
















Twelve Months Ended September 30, (continued)

























(Unaudited; Amounts in millions)




















































A


B


C=A+B


D


E


F=D+E


G



H=(C-F-G)/F






CFN


Comparable


BD


CFN


Comparable


Comparable



Comparable



Reported


Reported


Historical


Reported


Reported


Historical


FX



FXN



2015


1st Half 2015 *


2015


2014


2014


2014


Impact



% Change

BD MEDICAL 

























   Medication and Procedural Solutions


$

1,367


$

117


$

1,483


$

1,292


$

240


$

1,532


$

(154)



6.9

   Medication Management Solutions



201



208



409



-



416



416



(55)



11.6

   Diabetes Care



521



-



521



557



-



557



(69)



6.0

   Pharmaceutical Systems



863



-



863



926



-



926



(124)



6.7

   Respiratory Solutions



122



138



260



-



267



267



(22)



5.8

TOTAL


$

3,074


$

463


$

3,536


$

2,774


$

923


$

3,697


$

(426)



7.2

























BD LIFE SCIENCES

























   Preanalytical Systems


$

701


$

-


$

701


$

734


$

-


$

734


$

(90)



7.8

   Diagnostic Systems



708



-



708



728



-



728



(84)



8.7

   Biosciences



730



-



730



793



-



793



(69)



0.8

TOTAL


$

2,139


$

-


$

2,139


$

2,255


$

-


$

2,255


$

(244)



5.7


















































TOTAL INTERNATIONAL


$

5,213


$

463


$

5,675


$

5,029


$

923


$

5,952


$

(669)



6.6



































































































* For the quarters ended December 31, 2014 and March 31, 2015















































 

 

BECTON DICKINSON AND COMPANY






























SUPPLEMENTAL INFORMATION






























RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED FXN REVENUE CHANGE - TOTAL





















Twelve Months Ended September 30, (continued)






























(Unaudited; Amounts in millions)






























































A


B


C=A+B


D


E=C+D


F


G


H=F+G


I


J=(E-H-I)/H















Comparable














Comparable






Deferred 





CFN


Historical


BD


CFN


Comparable


Comparable


Adjusted



Reported


Revenue


Adjusted


Reported


Adjusted


Reported


Reported


Historical


FX


FXN



2015


Adjustment


2015


1st Half 2015 **


2015


2014


2014


2014


Impact


% Change

BD MEDICAL 






























   Medication and Procedural Solutions


$

2,850


$

-


$

2,850


$

544


$

3,394


$

2,307


$

1,040


$

3,347


$

(154)


6.0

   Medication Management Solutions



1,033



-



1,033



1,051



2,084



-



2,023



2,023



(55)


5.7

   Diabetes Care



1,012



-



1,012



-



1,012



1,037



-



1,037



(69)


4.3

   Pharmaceutical Systems



1,167



-



1,167



-



1,167



1,229



-



1,229



(124)


5.1

   Respiratory Solutions



419



-



419



471



890



-



871



871



(22)


4.7

   Deferred Revenue Adjustment *



(20)



20



-



-



-



-



-



-



-


-

TOTAL


$

6,460


$

20


$

6,480


$

2,066


$

8,547


$

4,573


$

3,934


$

8,507


$

(426)


5.5





























BD LIFE SCIENCES





























   Preanalytical Systems


$

1,391


$

-


$

1,391


$

-


$

1,391


$

1,412


$

-


$

1,412


$

(90)


4.9

   Diagnostic Systems



1,299



-



1,299



-



1,299



1,301



-



1,301



(84)


6.3

   Biosciences



1,132



-



1,132



-



1,132



1,159



-



1,159



(69)


3.6

TOTAL


$

3,822


$

-


$

3,822


$

-


$

3,822


$

3,872


$

-


$

3,872


$

(244)


5.0


























































TOTAL REVENUES


$

10,282


$

20


$

10,302


$

2,066


$

12,368


$

8,446


$

3,934


$

12,380


$

(669)


5.3






















































































































* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date.  The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

































** For the quarters ended December 31, 2014 and March 31, 2015

























































 

 

BECTON DICKINSON AND COMPANY
















SUPPLEMENTAL REVENUE INFORMATION
















SAFETY REVENUES
















(Unaudited; Amounts in millions)


















































Three Months Ended September 30,



A


B


C



D=(A-B)/B



E=(A-B-C)/B



As Reported


FX



 % Change 



2015



2014


Impact



 Reported 



 FXN 

TOTAL SAFETY REVENUES
















   United States


$

441


$

301


$

-



46.6



46.6

   International



303



265



(49)



14.1



32.7

TOTAL


$

744


$

566


$

(49)



31.3



40.0

















BY SEGMENT
















   BD Medical


$

468


$

287


$

(26)



63.3



72.4

   BD Life Sciences



276



279



(23)



(1.4)



6.8

TOTAL


$

744


$

566


$

(49)



31.3



40.0



















































































Twelve Months Ended September 30,



A


B


C



D=(A-B)/B



E=(A-B-C)/B



As Reported


FX



 % Change 



2015



2014


Impact



 Reported 



 FXN 

TOTAL SAFETY REVENUES
















   United States


$

1,471


$

1,207


$

-



21.8



21.8

   International



1,128



1,016



(142)



10.9



24.9

TOTAL


$

2,598


$

2,223


$

(142)



16.9



23.3

















BY SEGMENT
















   BD Medical


$

1,501


$

1,119


$

(74)



34.1



40.7

   BD Life Sciences



1,097



1,104



(69)



(0.7)



5.6

TOTAL


$

2,598


$

2,223


$

(142)



16.9



23.3

















 

 

BECTON DICKINSON AND COMPANY

























SUPPLEMENTAL INFORMATION

























RECONCILIATION OF SAFETY REVENUE CHANGE TO COMPARABLE FXN REVENUE CHANGE



















(Unaudited; Amounts in millions)




















































Three Months Ended September 30,









A


B


C


D=B+C


E



F=(A-D-E)/D









BD


BD


CFN


Comparable


Comparable



Comparable









Reported


Reported


Reported


Historical


FX



FXN









2015


2014


2014


2014


Impact



% Change







TOTAL SAFETY REVENUES

























   United States


$

441


$

301


$

122


$

422


$

-



4.4







   International



303



265



45



311



(49)



13.4







TOTAL


$

744


$

566


$

167


$

733


$

(49)



8.2
































BY SEGMENT

























   BD Medical


$

468


$

287


$

167


$

453


$

(26)



9.0







   BD Life Sciences



276



279



-



279



(23)



6.8







TOTAL


$

744


$

566


$

167


$

733


$

(49)



8.2













































































































Twelve Months Ended September 30,



A


B


C=A+B


D


E


F=D+E


G



H=(C-F-G)/F






CFN


Comparable


BD


CFN


Comparable


Comparable



Comparable



Reported


Reported


Historical


Reported


Reported


Historical


FX



FXN



2015


1st Half 2015 *


2015


2014


2014


2014


Impact



% Change

TOTAL SAFETY REVENUES

























   United States


$

1,471


$

252


$

1,722


$

1,207


$

470


$

1,677


$

-



2.7

   International



1,128



83



1,210



1,016



172



1,188



(149)



14.4

TOTAL


$

2,598


$

334


$

2,932


$

2,223


$

641


$

2,865


$

(149)



7.6


























BY SEGMENT

























   BD Medical


$

1,501


$

334


$

1,835


$

1,119


$

641


$

1,760


$

(80)



8.8

   BD Life Sciences



1,097



-



1,097



1,104



-



1,104



(69)



5.6

TOTAL


$

2,598


$

334


$

2,932


$

2,223


$

641


$

2,865


$

(149)



7.6



















































* For the quarters ended December 31, 2014 and March 31, 2015






















 

 

BECTON DICKINSON AND COMPANY

























SUPPLEMENTAL INFORMATION

























RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS






















(Unaudited)























































Three Months Ended September 30,


















Foreign






Foreign















Foreign


 Currency






 Currency















Currency


Neutral






Neutral






2015


2014


Growth


Translation


Growth



Growth %



Growth %


























Reported Diluted Earnings per Share


$

0.84


$

1.53


$

(0.69)


$

(0.17)


$

(0.52)



(45.1%)



(34.0%)


























Transaction Costs ($7 million or $4 million after-tax and $6 million or $4 million after-tax, respectively) (1)



0.02



0.02









































Integration Costs ($40 million or $25 million after-tax) (1)



0.12



-









































Restructuring Costs ($135 million or $84 million after-tax) (1)



0.39



-









































Purchase Accounting Adjustments ($179 million or $125 million after-tax and $18 million or $13 million after-tax, respectively)



0.58

(2)

0.06

(3)




(0.01)
































Employee Termination Cost-related Amounts ($36 million or $23 million after-tax) (4)



-



0.12









































Research and Development Adjustment ($(4) million or $(2) million after-tax) (5)



-



(0.01)








































Pension Settlement Charges ($3 million or $2 million after-tax) (6)



-



0.01








































Other Specified Items, Net ($5 million or $3 million after-tax) (7)



-



0.02








































Adjusted Diluted Earnings per Share


$

1.94


$

1.74


$

0.20


$

(0.18)


$

0.38



11.5%



21.8%



















































(1) Represents transaction, integration and restructuring costs associated with the CareFusion acquisition.



























(2) Represents non-cash amortization expense of $152 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $27 million pre-tax to reflect CareFusion's inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date.



























(3) Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.



























(4) Represents amounts recorded to a liability for employee termination costs associated with workforce reduction actions taken in the fourth quarter of fiscal year 2014.



























(5) Represents a revision to the estimated probable loss previously recorded as a result of the decision to terminate a research and development program in the Medical segment.





























(6) Represents non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost in each year. The charges also included settlement losses associated with certain foreign pension plans.





























(7) Represents a charge resulting from the adjustment to the carrying amount of an asset that is being held for sale.




 

 

 

BECTON DICKINSON AND COMPANY

























SUPPLEMENTAL INFORMATION

























RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS






















(Unaudited)























































Twelve Months Ended September 30,


















Foreign






Foreign















Foreign


 Currency






 Currency















Currency


Neutral






Neutral






2015


2014


Growth


Translation


Growth



Growth %



Growth %


























Reported Diluted Earnings per Share





$

3.35


$

5.99


$

(2.64)


$

(0.69)


$

(1.95)



(44.1%)



(32.6%)


























Financing Costs ($107 million or $65 million after-tax) (1)



0.31



-









































Transaction Costs ($59 million or $39 million after-tax and $6 million or $4 million after-tax, respectively) (1)



0.19



0.02









































Integration Costs ($95 million or $59 million after-tax) (1)



0.29



-









































Restructuring Costs ($271 million or $167 million after-tax) (1)



0.80



-









































Purchase Accounting Adjustments ($645 million or $451 million after-tax and $74 million or $51 million after-tax, respectively)



2.17

(2)

0.26

(3)




(0.02)



































Employee Termination Cost-related Amounts ($(5) million or $(3) million after-tax and $36 million or $23 million after-tax, respectively) (4)



(0.01)



0.12






































Litigation-related Charge ($12 million or $7 million after-tax) (5)



0.04



-









































Dilutive Share Impact (6)






0.02



-









































Research and Development Charges ($26 million or $16 million after-tax) (7)



-



0.08









































Pension Settlement Charges ($3 million or $2 million after-tax) (8)



-



0.01









































Other Specified Items, Net ($8 million or $6 million after-tax) (9)



-



0.03









































Adjusted Diluted Earnings per Share





$

7.16


$

6.50


$

0.66


$

(0.72)


$

1.38



10.2%



21.2%



















































(1) Represents financing, transaction, integration and restructuring costs associated with the CareFusion acquisition.



























(2) Represents non-cash amortization expense of $336 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $318 million pre-tax to reflect CareFusion's inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date.  Also includes an acquisition-date accounting gain on a previously held investment in CRISI Medical Systems, Inc. of $9 million pre-tax.



























(3) Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.



























(4) Represents amounts recorded to a liability for employee termination costs associated with workforce reduction actions taken in the fourth quarter of fiscal year 2014.



























(5) Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI. 



























(6) Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The year-to-date adjusted diluted average shares outstanding (in thousands) is 206,833.



























(7) Includes a $6 million charge associated with the decision to terminate a research and development program in the Medical segment; the charge relates to program asset write-offs and obligations. Also includes a $20 million charge associated with the write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the Life Sciences segment.



























(8) Primarily represents non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost in each year. The charges also included settlement losses associated with certain foreign pension plans.





























(9) Represents the cost associated with the decision to early terminate a European distributor arrangement in the Life Sciences segment of $11 million pre-tax and a charge resulting from the adjustment to the carrying amount of an asset that is being held for sale of $5 million pre-tax, which were largely offset by a gain from a cash distribution received from the sale of a company, of which BD had a small equity ownership, of $8 million pre-tax. 




 

 

BECTON DICKINSON AND COMPANY





















SUPPLEMENTAL INFORMATION





















FY2016 OUTLOOK RECONCILIATION











































FY2016 Outlook








Revenues


FX Impact


FXN Basis
































Full Year FY2016 Estimated Growth on a Reported Basis


23.0% - 23.5%



~(1.5%)



24.5% - 25.0%













Deferred Revenue Adjustment


 NM 



 NM 



 NM 













Adjusted Full Year FY2016 Estimated Growth


23.0% - 23.5%



~(1.5%)



24.5% - 25.0%













































































Full Year


Full Year















FY2016


FY2015


% Increase












(estimated)








































Reported Fully Diluted Earnings per Share 

$

6.57 - 6.64


$

3.35



NM


































Financing Costs


-



0.31





































Transaction Costs


-



0.19





































Integration Costs 


-



0.29





































Restructuring Costs


-



0.80





































Purchase Accounting Adjustments


1.80



2.17





































Employee Termination Cost-related Amounts


-



(0.01)





































Litigation-related Charge


-



0.04





































Dilutive Share Impact


-



0.02





































Adjusted Fully Diluted Earnings per Share 

$

8.37 - 8.44


$

7.16



17.0% - 18.0%


































FX Impact

$

(0.36)






(5.0%)

































Adjusted FXN Growth

$

8.73 - 8.80






22.0% - 23.0%












































































Organic Revenues Growth



































Full Year



Full Year






Q1



Q2



Q3



Q4



FY2015



FY2016





















(estimated)

























CareFusion Revenues, Reported


16.1%



3.0%



(5.2%)



1.2%



3.3%



~2.0%




FX Impact


(1.4%)



(2.4%)



(3.2%)



(2.8%)



(2.5%)



~(0.5%)




CareFusion Revenues, FXN


17.5%



5.4%



(2.0%)



4.0%



5.8%



~2.5%




CareFusion Inorganic Revenues, FXN


(7.6%)



-



(0.2%)



(0.6%)



(2.0%)



~1.5%




CareFusion Organic Revenues, FXN (1)


9.9%



5.4%



(2.2%)



3.4%



3.8%



~4.0%

























BD Standalone Revenues, Reported


1.8%



(1.0%)



(4.1%)



(3.1%)



(1.7%)



~3.0%




FX Impact


(3.5%)



(5.9%)



(8.7%)



(8.6%)



(6.8%)



~(2.0%)




BD Standalone Revenues, FXN


5.3%



4.9%



4.7%



5.5%



5.1%



~5.0%




BD Standalone Inorganic Revenues, FXN


 NM 



 NM 



(0.1%)



 NM 



 NM 



 NM 




BD Standalone Organic Revenues, FXN


5.3%



4.9%



4.6%



5.5%



5.1%



~5.0%

























CareFusion Organic Revenues, FXN(1)














3.8%



~4.0%




BD Standalone Organic Revenues, FXN














5.1%



~5.0%




BD Including CareFusion Organic Revenues, FXN














4.7%



4.5%-5.0%














































NM - Not Meaningful





















FXN = Foreign Currency Neutral










































(1) Excludes the impact from a distribution agreement change in the Respiratory Solutions business.


 

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Kristen Cardillo, Corporate Communications – 858-617-2317

SOURCE BD (Becton, Dickinson and Company)



RELATED LINKS

http://www.bd.com